• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Pediatric FOP Study Results Change Mirum Pharmaceuticals Stock Narrative

    Simply Wall St·10/31/2026 15:38:07
    Listen to the news
    • Mirum Pharmaceuticals reported past positive results from Cohort 2 of the PROGRESS trial of ATEBRIOZ in children aged 6 to under 12 with fibrodysplasia ossificans progressiva, with reduced heterotopic ossification lesion volume, better joint mobility scores and a tolerability profile consistent with earlier data.
    • The data extend ATEBRIOZ beyond already approved older patients and point to a potentially broader treated FOP population and deeper use of Mirum's rare disease infrastructure.
    • The focus now turns to how Mirum Pharmaceuticals' investment narrative absorbs these pediatric joint mobility gains and what that could mean for future earnings mix.
    Capitalize on Mirum Pharmaceuticals' rare disease momentum by lining up other potential breakout opportunities from our hand-picked 18 high quality undiscovered gems in adjacent high-specialty niches.

    Mirum Pharmaceuticals Investment Narrative Recap

    To own Mirum Pharmaceuticals, you need to believe its rare disease portfolio can shift from a Livmarli heavy story to a more balanced mix that includes ATEBRIOZ and other assets. The new pediatric PROGRESS data fits that thesis by suggesting Mirum may be able to serve FOP patients earlier in the disease course, using the same commercial infrastructure.

    The near term swing factor still looks like execution on current product uptake and reimbursement in the US and abroad, as well as managing losses and negative equity. The Cohort 2 readout supports pipeline depth but does not remove key risks around pricing pressure, R&D spending and future competition in rare disorders.

    The most relevant recent development is the September 2026 US FDA approval of ATEBRIOZ for adults and adolescents aged 12 years and older with FOP, backed by PROGRESS Cohort 1. The fresh Cohort 2 results in 6 to under 12 year olds now sit directly on top of that approval and provide investors with more real world clinical context around this drug.

    For catalysts, you can now consider ATEBRIOZ alongside Livmarli and the late stage programs such as VISTAS, VANTAGE and EXPAND when assessing how Mirum Pharmaceuticals may diversify revenue over time. The same risks still apply, particularly the reliance on a small number of high value indications and exposure to orphan pricing scrutiny, even as the company relies on its rare disease infrastructure.

    Mirum Pharmaceuticals' current analyst narrative points to US$1.3b in revenue and US$324.9 million in earnings by 2029, based on an assumed 26.5% yearly top line expansion and an earnings swing of roughly US$1.19b from a loss of US$860.2 million today to that 2029 consensus level.

    Uncover why Mirum Pharmaceuticals' fair value indicates an 80% potential upside to its current price that could narrow quickly.

    NasdaqGM:MIRM 1-Year Stock Price Chart
    NasdaqGM:MIRM 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate angle to watch is how bullish analysts already treated ATEBRIOZ as a future revenue pillar for Mirum Pharmaceuticals, even before this Cohort 2 update. That group was modeling about US$1.4b in 2029 revenue and US$642.9 million in earnings, far above consensus, so your takeaway may shift if and when those forecasts are revisited.

    Explore 2 other Mirum Pharmaceuticals fair value estimates, including one that suggests potential upside of up to 362% from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Mirum Pharmaceuticals?

    If Mirum Pharmaceuticals has you thinking about how rare disease exposure fits into your broader portfolio, it can help to line it up against other opportunities with clear financial profiles. The Simply Wall St Screener lets you scan a wide range of companies through different lenses so you can decide where risk, quality and income best suit your approach.

    • For investors hunting for quality at a reasonable entry point, start with a carefully filtered group of 29 high quality undervalued stocks that pair fundamentals with pricing that may not fully reflect them yet.
    • If balance sheet resilience is your priority, focus on financially sturdy businesses by working through a curated list of solid balance sheet and fundamentals (25 results) that highlights stronger net cash positions and cleaner liabilities.
    • Those who care most about limiting downside can concentrate on stability first by reviewing a 30 resilient stocks with low risk scores that screens for companies with lower overall risk scores based on multiple factors.